S
IGMS

SignatureFD’s IGM Biosciences IGMS Stock Holding History

SignatureFD’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-161
Closed -$984 – 3371
2024
Q4 		$984 Hold
161
– – ﹤0.01% 3032
2024
Q3 		$2.66K Sell
161
-30
-16% -$329 ﹤0.01% 2754
2024
Q2 		$1.31K Buy
191
+4
+2% +$34 ﹤0.01% 2849
2024
Q1 		$1.8K Buy
187
+157
+523% +$1.82K ﹤0.01% 2826
2023
Q4 		$249 Hold
30
– – ﹤0.01% 3039
2023
Q3 		$251 Sell
30
-271
-90% -$2.3K ﹤0.01% 3078
2023
Q2 		$2.78K Sell
301
-324
-52% -$3.63K ﹤0.01% 2701
2023
Q1 		$8.59K Sell
625
-152
-20% -$3.14K ﹤0.01% 2281
2022
Q4 		$13.2K Sell
777
-113
-13% -$2.26K ﹤0.01% 2007
2022
Q3 		$20K Buy
890
+118
+15% +$2.38K ﹤0.01% 1730
2022
Q2 		$14K Buy
772
+287
+59% +$5.12K ﹤0.01% 1949
2022
Q1 		$13K Buy
+485
New +$9.03K ﹤0.01% 2041
2021
Q4 		– Sell
-11
Closed -$1K – 3176
2021
Q3 		$1K Buy
+11
New +$842 ﹤0.01% 2838

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SignatureFD's IGMS Position: Q1 2025 in Review

SignatureFD sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 161 shares — an estimated $984 sold.

SignatureFD first reported a position in IGMS in Q3 2021 and held it in 13 quarters. The position peaked at $20K in Q3 2022. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • SignatureFD reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • SignatureFD sold 161 IGM Biosciences shares in Q1 2025, an estimated $984.
  • SignatureFD first reported a position in IGM Biosciences in Q3 2021 and held it in 13 quarters.
  • SignatureFD's IGM Biosciences position peaked at $20K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.